Amol Ambadas Tagalpallewar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Amol Ambadas Tagalpallewar has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Akshay Motilal Baheti
School of Health Sciences and Technology, Dr. Vishwanath Karad MIT World Peace University, Pune, India
5 shared publications - Anil Tukaram Pawar
School of Health Sciences and Technology, Dr. Vishwanath Karad MIT World Peace University, Pune, India
5 shared publications - Manasi R. Nimbalkar
Department of Kriya Sharir, Ashtang Ayurved Mahavidyalaya, Pune, India
5 shared publications Akshay M. Baheti
School of Health Sciences and Technology, Dr. Vishwanath Karad MIT World Peace University, Pune, India
4 shared publicationsRanjit G. Nimbalkar
Ayurveda Practitioner, Anubandha Health Care, Tilak Road, Pune, India
4 shared publicationsAkshay Baheti
3 shared publications
Latest Publications
- Open Access
- 13 October 2026
- Published by Elsevier in Journal of Ayurveda and Integrative Medicine
- Vol. 17 (5) , 101390
Management of post-operative delayed proximal tibia and fibula fracture with Ayurvedic medicines and Panchakarma: A case report
- 13 October 2026
- Published by Elsevier in Journal of Ayurveda and Integrative Medicine
- Vol. 17 (5) , 101390
Open AccessManagement of post-operative delayed proximal tibia and fibula fracture with Ayurvedic medicines and Panchakarma: A case report
- Open Access
- 25 May 2026
- Published by Elsevier in Journal of Ayurveda and Integrative Medicine
- Vol. 17 (3) , 101340
A recurrent hepatocellular carcinoma with incomplete response to conventional treatments, showing substantial regression and good quality of life by Ayurveda treatment: A case report
- 25 May 2026
- Published by Elsevier in Journal of Ayurveda and Integrative Medicine
- Vol. 17 (3) , 101340
Open AccessA recurrent hepatocellular carcinoma with incomplete response to conventional treatments, showing substantial regression and good quality of life by Ayurveda treatment: A case report
- Open Access
- 12 March 2026
- Published by Elsevier in Journal of Ayurveda and Integrative Medicine
- Vol. 17 (2) , 101325
Three years of chemotherapy tolerance with concurrent Ayurvedic treatment in a metastatic lung adenocarcinoma: A case report
- 12 March 2026
- Published by Elsevier in Journal of Ayurveda and Integrative Medicine
- Vol. 17 (2) , 101325
Open AccessThree years of chemotherapy tolerance with concurrent Ayurvedic treatment in a metastatic lung adenocarcinoma: A case report
- Open Access
- 20 November 2025
- Published by Elsevier in Journal of Ayurveda and Integrative Medicine
- Vol. 16 (6) , 101267
Anti-inflammatory effects of Glycyrrhiza glabra homeopathic formulations in a rat model of lipopolysaccharide-induced inflammation
- 20 November 2025
- Published by Elsevier in Journal of Ayurveda and Integrative Medicine
- Vol. 16 (6) , 101267
Open AccessAnti-inflammatory effects of Glycyrrhiza glabra homeopathic formulations in a rat model of lipopolysaccharide-induced inflammation
- Open Access
- 18 July 2024
- Published by Elsevier in Journal of Ayurveda and Integrative Medicine
- Vol. 15 (4) , 100976
Five years of disease-free survival in a case of recurrent, post-op, grade 3, stage 2, Malignant Spindle Cell Melanoma treated with Ayurvedic medicines: A case report
- 18 July 2024
- Published by Elsevier in Journal of Ayurveda and Integrative Medicine
- Vol. 15 (4) , 100976
Open AccessFive years of disease-free survival in a case of recurrent, post-op, grade 3, stage 2, Malignant Spindle Cell Melanoma treated with Ayurvedic medicines: A case report
- Open Access
- 1 February 2024
- Published by Elsevier in Journal of Ayurveda and Integrative Medicine
- Vol. 15 (1) , 100881
Eleven years of disease free survival in a case of Invasive Ductal Carcinoma (IDC) Rt Breast grade 3, stage 3, treated with add on Ayurveda treatment: A case report
- 1 February 2024
- Published by Elsevier in Journal of Ayurveda and Integrative Medicine
- Vol. 15 (1) , 100881
Open AccessEleven years of disease free survival in a case of Invasive Ductal Carcinoma (IDC) Rt Breast grade 3, stage 3, treated with add on Ayurveda treatment: A case report
- Open Access
- 22 January 2024
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 25 (2)
Integrating network pharmacology and in silico analysis deciphers Withaferin-A’s anti-breast cancer potential via hedgehog pathway and target network interplay
This study examines the remarkable effectiveness of Withaferin-A (WA), a withanolide obtained from Withania somnifera (Ashwagandha), in encountering the mortiferous breast malignancy, a global peril. The predominant objective is to investigate WA’s intrinsic target proteins and hedgehog (Hh) pathway proteins in breast cancer targeting through the application of in silico computational techniques and network pharmacology predictions. The databases and webtools like Swiss target prediction, GeneCards, DisGeNet and Online Mendelian Inheritance in Man were exploited to identify the common target proteins. The culmination of the WA network and protein–protein interaction network were devised using Stitch and String web tools, through which the drug–target network of 30 common proteins was constructed employing Cytoscape-version 3.9. Enrichment analysis was performed by incorporating Gprofiler, Metascape and Cytoscape plugins. David compounded the Gene Ontology and Kyoto Encyclopedia of Genes and Genomes, and enrichment was computed through bioinformatics tools. The 20 pivotal proteins were docked harnessing Glide, Schrodinger Suite 2023-2. The investigation was governed by docking scores and affinity. The shared target proteins underscored the precise Hh and WA network roles with the affirmation enrichment P-value of P < 0.01). Further, the ADMET and drug-likeness assessments assisted the claim. Robust interactions were noticed with docking studies, authenticated through molecular dynamics, molecular mechanics generalized born surface area scores and bonds. The computational investigation emphasized WA’s credible anti-breast activity, specifically with Hh proteins, implying stem-cell-level checkpoint restraints. Rigorous testament is imperative through in vitro and in vivo studies.
- 22 January 2024
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 25 (2)
Open AccessIntegrating network pharmacology and in silico analysis deciphers Withaferin-A’s anti-breast cancer potential via hedgehog pathway and target network interplay
This study examines the remarkable effectiveness of Withaferin-A (WA), a withanolide obtained from Withania somnifera (Ashwagandha), in encountering the mortiferous breast malignancy, a global peril. The predominant objective is to investigate WA’s intrinsic target proteins and hedgehog (Hh) pathway proteins in breast cancer targeting through the application of in silico computational techniques and network pharmacology predictions. The databases and webtools like Swiss target prediction, GeneCards, DisGeNet and Online Mendelian Inheritance in Man were exploited to identify the common target proteins. The culmination of the WA network and protein–protein interaction network were devised using Stitch and String web tools, through which the drug–target network of 30 common proteins was constructed employing Cytoscape-version 3.9. Enrichment analysis was performed by incorporating Gprofiler, Metascape and Cytoscape plugins. David compounded the Gene Ontology and Kyoto Encyclopedia of Genes and Genomes, and enrichment was computed through bioinformatics tools. The 20 pivotal proteins were docked harnessing Glide, Schrodinger Suite 2023-2. The investigation was governed by docking scores and affinity. The shared target proteins underscored the precise Hh and WA network roles with the affirmation enrichment P-value of P < 0.01). Further, the ADMET and drug-likeness assessments assisted the claim. Robust interactions were noticed with docking studies, authenticated through molecular dynamics, molecular mechanics generalized born surface area scores and bonds. The computational investigation emphasized WA’s credible anti-breast activity, specifically with Hh proteins, implying stem-cell-level checkpoint restraints. Rigorous testament is imperative through in vitro and in vivo studies.